BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:22 PM
 | 
Mar 01, 2007
 |  BC Extra  |  Clinical News

Merck's Isentress meets HIV endpoint

MRK said interim 16-week data showed Isentress raltegravir ( MK-0518) plus optimized background therapy (OBT) met the primary endpoint of a significant reduction in HIV viral load...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >